查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1811744

全球醫療CMO市場（2025年版）

Global Healthcare CMO Market: 2025 Edition
出版日期: | 出版商: Daedal Research | 英文 144 Pages | 訂單完成後即時交付

價格

醫療保健CMO（受託製造廠商）是指依據法律協議，在一定期限內提供藥品開發和製造等綜合服務的公司。預計全球醫療保健CMO市場規模到2023年將達到1,458.3億美元，到2029年將達到2,912.5億美元。

多年來，醫療保健CMO市場呈現顯著成長，主要原因是慢性病發病率上升和全球人口老化導致對藥品和生物製藥的需求不斷成長。製藥公司也擴大將生產外包給CMO，以降低成本並致力於核心競爭力。製造技術和過程的進步使CMO能夠提供高品質、可擴展且經濟高效的生產解決方案。其他主要趨勢包括人工智慧技術、個人化醫療、永續性和綠色製造、先進製造技術以及細胞和基因療法的擴展。預計全球醫療保健CMO市場在預測期內（2024-2029年）的年複合成長率將達到12.22%。

本報告調查並分析了全球醫療保健CMO市場，提供了各地區市場規模、成長動力和挑戰、市場趨勢和競爭格局的資訊。

目錄

第1章 執行摘要

第2章 簡介

  • 醫療受託製造廠商（CMO）：概述
    • 醫療CMO的優勢
  • 醫療保健CMO細分：概述
    • 醫療CMO的細分

第3章 全球市場分析

  • 全球醫療保健CMO市場：分析
    • 全球醫療CMO市場概覽
    • 全球醫療CMO市場規模
    • 全球醫療CMO市場：依類型（藥品、醫療設備）
    • 全球醫療CMO市場：依地區（北美、歐洲、亞太地區、世界其他地區）
  • 全球醫療CMO市場：類型分析
    • 全球醫療CMO市場：依類型，概覽
    • 全球醫藥CMO市場規模
    • 全球製藥CMO市場：依服務（原料藥（API）、其他）
    • 全球醫療設備CMO市場規模
  • 全球製藥CMO市場：服務分析
    • 全球製藥CMO市場：依服務，概覽
    • 全球原料藥（API）CMO 市場規模
    • 其他製藥CMO的全球市場規模

第4章 區域市場分析

  • 北美醫療保健CMO市場：分析
    • 北美醫療CMO市場概覽
    • 北美醫療CMO市場規模
    • 北美醫療CMO市場：依地區（美國、加拿大、墨西哥）
    • 美國醫療CMO市場規模
    • 美國醫療CMO市場：依類型（藥品、醫療設備）
    • 美國製藥與醫療CMO市場規模
    • 美國醫療設備CMO市場規模
    • 加拿大醫療保健CMO市場規模
    • 墨西哥醫療CMO市場規模
  • 歐洲醫療保健CMO市場：分析
    • 歐洲醫療CMO市場概覽
    • 歐洲醫療CMO市場規模
    • 歐洲醫療保健 CMO市場：依地區（德國、英國、法國、義大利、西班牙、歐洲其他地區）
    • 德國醫療CMO市場規模
    • 英國醫療保健CMO市場規模
    • 法國醫療CMO市場規模
    • 義大利醫療CMO市場規模
    • 西班牙醫療保健CMO市場規模
    • 其他歐洲醫療CMO市場規模
  • 亞太醫療保健CMO市場：分析
    • 亞太醫療CMO市場概覽
    • 亞太醫療CMO市場規模
    • 亞太醫療 CMO市場：依地區（中國、日本、印度、韓國、亞太其他地區）
    • 中國醫療CMO市場規模
    • 日本醫療CMO市場規模
    • 印度醫療CMO市場規模
    • 韓國醫療CMO市場規模
    • 其他亞太地區醫療保健CMO市場規模
  • 全球其他地區醫療保健CMO市場：分析
    • 全球其他地區醫療保健CMO市場：概覽
    • 其他醫療CMO的全球市場規模

第5章 COVID-19 的影響

  • COVID-19 對全球醫療CMO市場的影響
  • CDMO外包業務快速成長
  • COVID後情況

第6章 市場動態

  • 成長動力
    • 老年人口快速成長
    • 醫療費用上漲
    • 慢性病日益蔓延
    • 學名藥需求不斷成長
    • 經濟高效
    • 生物製藥製造的複雜性
    • 對原料藥（API）的需求不斷增加
  • 課題
    • 監理合規
    • 依賴專利、版權、商標和商業機密
  • 市場趨勢
    • 人工智慧技術的作用不斷擴大
    • 個人化醫療
    • 永續性和綠色製造
    • 先進製造技術
    • 細胞和基因治療的擴展
    • 尋找替代表現系統
    • 人們對草藥產品的興趣日益濃厚

第7章 競爭態勢

  • 全球醫療保健CMO市場：競爭格局
  • 全球醫療CMO市場公司：財務比較

第8章 公司簡介

  • Catalent Pharma Solutions Inc.
  • Samsung Biologics Co. Ltd.
  • Aurobindo Pharma Limited
  • Boehringher Ingelheim
  • Integer Holdings Corporation
  • Piramal Pharma Limited
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Fareva Group
  • Symbiosis Pharmaceutical Services
  • Cytovance Biologics
  • Curia

Healthcare CMOs, or healthcare contract manufacturing organizations, are companies that provide comprehensive services such as drug development and manufacturing for a set period of time under a legal contract. The global healthcare CMO market was valued at US$145.83 billion in 2023, and is predicted to grow to US$291.25 billion in 2029.

The healthcare CMO market has experienced significant growth over the years primarily due to the increasing demand for pharmaceutical and biopharmaceutical products, spurred by the rising prevalence of chronic diseases and the aging global population. Also, the trend of pharmaceutical companies outsourcing manufacturing to CMOs to reduce costs and focus on core competencies has contributed significantly to market expansion. Advancements in manufacturing technologies and processes have also enabled CMOs to offer high-quality, scalable, and cost-effective production solutions. Other significant trends include escalating role of artificial intelligence technology, personalized medicine, sustainability and green manufacturing, advanced manufacturing technologies, expansion in cell and gene therapy etc. The global healthcare CMO market is determined to grow at a CAGR of 12.22% over the forecasted period of 2024-2029.

Market Segmentation Analysis:

By Type: The report identifies two segments on the basis of type: Pharmaceutical and Medical Device. The pharmaceuticals manufacturing segment acquired majority of share in the market in 2023 and is expected to grow at the fastest rate in the market during the forecast period, owing to increasing prevalence of chronic diseases and the rising global demand for complex drugs has driven pharmaceutical companies to outsource manufacturing to CMOs. Additionally, the surge in the development of complex biologics, personalized medicines, and specialty drugs necessitates advanced manufacturing capabilities, which many CMOs possess. Further, the ongoing advancements in pharmaceutical manufacturing technologies, coupled with the trend towards outsourcing, are expected to sustain and accelerate the growth of the pharmaceuticals manufacturing segment in the healthcare CMO market. Pharmaceutical CMO segment is further divided into two segments on the basis of service: Active Pharmaceutical Ingredients (API) and Others.

By Region: In the report, the global healthcare CMO market is divided into four regions: North America, Europe, Asia Pacific, and ROW. North America accounted for the maximum share of the global market in 2023. The market in North America is being driven by the region's increased emphasis on drug discovery and manufacturing outsourcing. The region is increasing its use of scientific exploration of disease mechanisms leading to the discovery and development of agents. Pre-clinical testing is an important stage in pharmaceutical research. At this stage, several tests are performed to determine whether a drug is ready for clinical trials.

Asia Pacific is predicted to grow at a significantly high rate during the forecasted period because the region offers substantial cost advantages, including lower labor and operational costs, making it an attractive hub for manufacturing activities. Many countries in Asia Pacific, such as China and India, have invested heavily in developing their pharmaceutical and biotechnology infrastructure, providing state-of-the-art facilities and expertise. Secondly, the region has a large and growing population, increasing the demand for healthcare services and pharmaceutical products. This demographic shift is driving local and international pharmaceutical companies to expand their presence in Asia Pacific. Additionally, supportive government policies, including favorable regulations and incentives for foreign investment, have created a conducive environment for the growth of CMOs.

Market Dynamics:

Growth Drivers: One of the key drivers of the global healthcare CMO market's expansion is the increasing trend of pharmaceutical companies outsourcing their manufacturing processes. This strategic move allows pharmaceutical companies to reduce their operational costs significantly and focus more on their core competencies, such as research and development, marketing, and distribution. By partnering with CMOs, these companies can access advanced manufacturing technologies and expertise without the need for substantial capital investments in infrastructure. Outsourcing also provides flexibility in scaling production up or down based on demand, which is particularly beneficial in the rapidly evolving pharmaceutical market. This trend is bolstered by the growing complexity of drug manufacturing, especially with the rise of biologics and personalized medicines, which require specialized skills and equipment that many CMOs are equipped to provide. Other significant growth factors of the market include, surging geriatric population, rising healthcare expenditure, increasing spread of chronic diseases, escalating demand for generic drugs, and increasing demand for API.

Challenges: However, some challenges are impeding the growth of the market such as rapid technological advancement and dependent on patents, copyrights, trademarks and trade secrets. Industry players rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect many of company's offerings and intangible assets. The company's exclusive rights under certain of the offerings are protected by patents, some of which would expire in the near term. When patents covering an offering expire, loss of exclusivity may occur, which may force companies to compete with third parties, thereby negatively affecting the revenue and profitability and simultaneously hinders the growth of the industry.

Trends: The market is projected to grow at a fast pace during the forecast period, due to escalating role of artificial intelligence technology and evolution of advanced respiratory equipment. Healthcare artificial intelligence (AI) has transformed by assisting in repetitive tasks, designing treatment plans, medication management, and drug discovery. It can also be effectively used for healthcare data management by collecting, storing, and normalizing the data. Contract manufacturers are incorporating AI and other technological innovations to become more cost-effective and speed up production time. In addition, pharmaceutical CMOs are constantly developing AI technology in order to facilitate better risk detection and, in turn, improve the quality and safety of pharmaceutical products. The market is also projected to grow at a fast pace during the forecast period, due to various other latest trends such as personalized medicine, sustainability and green manufacturing, advanced manufacturing technologies, expansion in cell and gene therapy, exploration of alternative expression systems and growing inclination towards herbal products.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic had a positive demand shock, attributable to the increasing number of biopharmaceutical services provided to CMOs. CMOs invested in and acquired facilities in order to be ready for high-volume production units. This pandemic has proven to be an era of exponential growth in facility and bioprocessing units to have a higher output for increased and continuous supply.

Vaccine development and manufacturing activity in the healthcare CMO market has increased during pandemic, owing primarily to the industry's response to the COVID-19 pandemic. This expansion is expected to continue in the coming years as well. CMOs have made capacity and resource investments to address supply chain challenges. The CMO industry has seen an increase in modular construction and expansion, investments in cutting-edge technology, and process intensification strategies. Furthermore, many CMOs expanded their capabilities in new modalities such as [messenger RNA] mRNA and cell and gene therapy, which would drive the growth of the market during the post COVID period.

Competitive Landscape:

Global healthcare CMO market is fragmented. There is a wide array of CMOs ranging from large multinational corporations to small and mid-sized firms specializing in niche areas or regional markets. The key players in the healthcare CMO market provides a detailed competitive landscape and focus on launching novel products with the necessary approvals. There is a continuing need for research and development, which is still a key strategy among market players.

The key players in the global healthcare CMO market are:

Catalent Pharma Solutions, Inc.

Samsung Biologics Co. Ltd.

Aurobindo Pharma Limited

Boehringer Ingelheim GmbH

Integer Holdings Corporation

Piramal Enterprises Limited

Lonza Group AG

Thermo Fisher Scientific Inc.

Recipharm AB

Fareva Group

Symbiosis Pharmaceutical Services

Curia

Cytovance Biologics

These major players have been implementing novel strategies to expand market prospects in the coming years. On July 11, 2023, Recipharm Opens New Analytical Laboratory in Bangalore, India, to Increase Global Testing Capabilities for Nitrosamines, Extractables, Leachables, and Elemental Impurity Testing. 5,000 Sq Ft. Laboratory would support Recipharm's existing analytical capacity to support biotech and pharma customers in the Research and Development of Oral Solids, Drug Delivery, Inhalation, Vaccine, and Injectables with Full cGMP Compliance.

Table of Contents

1. Executive Summary

2. Introduction

  • 2.1 Healthcare Contract Manufacturing Organization (CMO): An Overview
    • 2.1.1 Benefits Of Healthcare CMOs
  • 2.2 Healthcare CMO Segmentation: An Overview
    • 2.2.1 Healthcare CMO Segmentation

3. Global Market Analysis

  • 3.1 Global Healthcare CMO Market: An Analysis
    • 3.1.1 Global Healthcare CMO Market: An Overview
    • 3.1.2 Global Healthcare CMO Market by Value
    • 3.1.3 Global Healthcare CMO Market by Type (Pharmaceutical and Medical Device)
    • 3.1.4 Global Healthcare CMO Market by Region (North America, Europe, Asia Pacific, and rest of the World (ROW)
  • 3.2 Global Healthcare CMO Market: Type Analysis
    • 3.2.1 Global Healthcare CMO Market by Type: An Overview
    • 3.2.2 Global Pharmaceutical CMO Market by Value
    • 3.2.3 Global Pharmaceutical CMO Market by Service (Active Pharmaceutical Ingredients (API) and Others)
    • 3.2.4 Global Medical Devices CMO Market by Value
  • 3.3 Global Pharmaceutical CMO Market: Service Analysis
    • 3.3.1 Global Pharmaceutical CMO Market by Service: An Overview
    • 3.3.2 Global Active Pharmaceutical Ingredients (API) CMO Market by Value
    • 3.3.3 Global Other Pharmaceuticals CMO Market by Value

4. Regional Market Analysis

  • 4.1 North America Healthcare CMO Market: An Analysis
    • 4.1.1 North America Healthcare CMO Market: An Overview
    • 4.1.2 North America Healthcare CMO Market by Value
    • 4.1.3 North America Healthcare CMO Market by Region (The US, Canada and Mexico)
    • 4.1.4 The US Healthcare CMO Market by Value
    • 4.1.5 The US Healthcare CMO Market by Type (Pharmaceutical and Medical Device)
    • 4.1.6 The US Pharmaceutical Healthcare CMO Market by Value
    • 4.1.7 The US Medical Devices Healthcare CMO Market by Value
    • 4.1.8 Canada Healthcare CMO Market by Value
    • 4.1.9 Mexico Healthcare CMO Market by Value
  • 4.2 Europe Healthcare CMO Market: An Analysis
    • 4.2.1 Europe Healthcare CMO Market: An Overview
    • 4.2.2 Europe Healthcare CMO Market by Value
    • 4.2.3 Europe Healthcare CMO Market by Region (Germany, The UK, France, Italy, Spain, and Rest of the Europe)
    • 4.2.4 Germany Healthcare CMO Market by Value
    • 4.2.5 The UK Healthcare CMO Market by Value
    • 4.2.6 France Healthcare CMO Market by Value
    • 4.2.7 Italy Healthcare CMO Market by Value
    • 4.2.8 Spain Healthcare CMO Market by Value
    • 4.2.9 Rest of Europe Healthcare CMO Market by Value
  • 4.3 Asia Pacific Healthcare CMO Market: An Analysis
    • 4.3.1 Asia Pacific Healthcare CMO Market: An Overview
    • 4.3.2 Asia Pacific Healthcare CMO Market by Value
    • 4.3.3 Asia Pacific Healthcare CMO Market by Region (China, Japan, India, South Korea, and Rest of the Asia Pacific)
    • 4.3.4 China Healthcare CMO Market by Value
    • 4.3.5 Japan Healthcare CMO Market by Value
    • 4.3.6 India Healthcare CMO Market by Value
    • 4.3.7 South Korea Healthcare CMO Market by Value
    • 4.3.8 Rest of Asia Pacific Healthcare CMO Market by Value
  • 4.4 Rest of World Healthcare CMO Market: An Analysis
    • 4.4.1 Rest of World Healthcare CMO Market: An Overview
    • 4.4.2 Rest of World Healthcare CMO Market by Value

5. Impact of COVID-19

  • 5.1 Impact of COVID-19 on Global Healthcare CMO Market
  • 5.2 Surge in Contracts to CDMOs
  • 5.3 Post-COVID Scenario

6. Market Dynamics

  • 6.1 Growth Drivers
    • 6.1.1 Surging Geriatric Population
    • 6.1.2 Rising Healthcare Expenditure
    • 6.1.3 Increasing Spread of Chronic Diseases
    • 6.1.4 Escalating Demand for Generic Drugs
    • 6.1.5 Cost Efficiency
    • 6.1.6 Complexity of Biologics Manufacturing
    • 6.1.7 Increasing Demand for Active Pharmaceutical Ingredient (API)
  • 6.2 Challenges
    • 6.2.1 Regulatory Compliance
    • 6.2.2 Dependent on Patents, Copyrights, Trademarks and Trade Secrets
  • 6.3 Market Trends
    • 6.3.1 Escalating Role of Artificial Intelligence Technology
    • 6.3.2 Personalized Medicine
    • 6.3.3 Sustainability and Green Manufacturing
    • 6.3.4 Advanced Manufacturing Technologies
    • 6.3.5 Expansion in Cell and Gene Therapy
    • 6.3.6 Exploration of Alternative Expression Systems
    • 6.3.7 Growing Inclination Towards Herbal Products

7. Competitive Landscape

  • 7.1 Global Healthcare CMO Market: Competitive Landscape
  • 7.2 Global Healthcare CMO Market Players: Financial Comparison

8. Company Profiles

  • 8.1 Catalent Pharma Solutions Inc.
    • 8.1.1 Business Overview
    • 8.1.2 Operating Segments
    • 8.1.3 Business Strategy
  • 8.2 Samsung Biologics Co. Ltd.
    • 8.2.1 Business Overview
    • 8.2.2 Operating Segments
    • 8.2.3 Business Strategy
  • 8.3 Aurobindo Pharma Limited
    • 8.3.1 Business Overview
    • 8.3.2 Operating Segments
    • 8.3.3 Business Strategy
  • 8.4 Boehringher Ingelheim
    • 8.4.1 Business Overview
    • 8.4.2 Operating Segments
    • 8.4.3 Business Strategy
  • 8.5 Integer Holdings Corporation
    • 8.5.1 Business Overview
    • 8.5.2 Operating Segments
    • 8.5.3 Business Strategy
  • 8.6 Piramal Pharma Limited
    • 8.6.1 Business Overview
    • 8.6.2 Net Revenue by Business Verticals
    • 8.6.3 Business Strategy
  • 8.7 Lonza Group AG
    • 8.7.1 Business Overview
    • 8.7.2 Operating Segments
    • 8.7.3 Business Strategy
  • 8.8 Thermo Fisher Scientific Inc.
    • 8.8.1 Business Overview
    • 8.8.2 Operating Segments
    • 8.8.3 Business Strategy
  • 8.9 Recipharm AB
    • 8.9.1 Business Overview
    • 8.9.2 Business Strategy
  • 8.10 Fareva Group
    • 8.10.1 Business Overview
    • 8.10.2 Business Strategy
  • 8.11 Symbiosis Pharmaceutical Services
    • 8.11.1 Business Overview
    • 8.11.2 Business Strategy
  • 8.12 Cytovance Biologics
    • 8.12.1 Business Overview
    • 8.12.2 Business Strategy
  • 8.13 Curia
    • 8.13.1 Business Overview
    • 8.13.2 Business Strategy

List of Tables

  • Table 1: Contracts Placed with Pharmaceutical CDMOs; 2020
  • Table 2: Global Healthcare CMO Market Players Financial Comparison; 2023

List of Figures

  • Figure 1: Benefits Of Healthcare CMOs
  • Figure 2: Healthcare CMO Segmentation
  • Figure 3: Global Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 4: Global Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 5: Global Healthcare CMO Market by Type; 2023 (Percentage, %)
  • Figure 6: Global Healthcare CMO Market by Region; 2023 (Percentage, %)
  • Figure 7: Global Pharmaceutical CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 8: Global Pharmaceutical CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 9: Global Pharmaceutical CMO Market by Service; 2023 (Percentage, %)
  • Figure 10: Global Medical Devices CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 11: Global Medical Devices CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 12: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 13: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 14: Global Other Pharmaceuticals CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 15: Global Other Pharmaceuticals CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 16: North America Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 17: North America Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 18: North America Healthcare CMO Market by Region; 2023 (Percentage, %)
  • Figure 19: The US Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 20: The US Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 21: The US Healthcare CMO Market by Type; 2023 (Percentage, %)
  • Figure 22: The US Pharmaceutical Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 23: The US Pharmaceutical Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 24: The US Medical Devices Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 25: The US Medical Devices Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 26: Canada Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 27: Canada Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 28: Mexico Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 29: Mexico Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 30: Europe Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 31: Europe Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 32: Europe Healthcare CMO Market by Region; 2023 (Percentage, %)
  • Figure 33: Germany Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 34: Germany Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 35: The UK Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 36: The UK Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 37: France Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 38: France Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 39: Italy Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 40: Italy Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 41: Spain Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 42: Spain Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 43: Rest of Europe Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 44: Rest of Europe Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 45: Asia Pacific Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 46: Asia Pacific Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 47: Asia Pacific Healthcare CMO Market by Region; 2023 (Percentage, %)
  • Figure 48: China Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 49: China Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 50: Japan Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 51: Japan Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 52: India Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 53: India Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 54: South Korea Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 55: South Korea Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 56: Rest of Asia Pacific Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 57: Rest of Asia Pacific Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 58: Rest of World Healthcare CMO Market by Value; 2019-2023 (US$ Billion)
  • Figure 59: Rest of World Healthcare CMO Market by Value; 2024-2029 (US$ Billion)
  • Figure 60: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
  • Figure 61: Health Expenditure per capita by Countries; 2021 and 2022 (US$ per capita)
  • Figure 62: Number of Individuals with Chronic Medical Conditions in the US; 2015-2050 (Million)
  • Figure 63: Global Generic Drugs Market Value, 2023-2031 (US$ Billion)
  • Figure 64: Global Artificial intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
  • Figure 65: Catalent, Inc. Net Revenue by Segments; 2023 (Percentage, %)
  • Figure 66: Samsung Biologics Co. Ltd. Revenue by Product Type; 2023 (Percentage, %)
  • Figure 67: Aurobindo Pharma Limited Revenue by Business Segments; 2023 (Percentage, %)
  • Figure 68: Boehringher Ingelheim Net Sales by Segments; 2023 (Percentage, %)
  • Figure 69: Integer Holdings Corporation Net Sales by Segments; 2023 (Percentage, %)
  • Figure 70: Piramal Pharma Limited Net Revenue by Business; 2023 (Percentage, %)
  • Figure 71: Lonza Group AG Sales by Segments; 2023 (Percentage, %)
  • Figure 72: Thermo Fisher Scientific Inc. Revenues by Segments; 2023 (Percentage, %)